At Myosana Therapeutics, patients are our enduring focus and motivation. Our mission is to develop new gene therapies that save lives, increase longevity, and improve quality of life for people with neuromuscular and cardiac genetic diseases.
02-foundingFounded in 2018 by Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., two internationally known experts in neuromuscular disease at the University of Washington School of Medicine, Myosana is pioneering muscle-directed non-viral gene therapy with a platform for neuromuscular and cardiac diseases.
02 historyIn his decades of muscle and Duchenne Muscular Dystrophy (DMD) research, Dr. Froehner played a pivotal role in discovery of the syntrophin proteins in muscle’s dystrophin complex. Dr. Whitehead, a muscle physiologist and DMD researcher, developed Myosana’s innovative muscle-targeted, non-viral platform.
muscle-cs-2Since Drs. Froehner and Whitehead founded Myosana, it has become the first company in the world to systemically deliver multiple doses of the full-length dystrophin gene to skeletal and cardiac muscle in a DMD animal model. Myosana has completed two successful funding rounds and is currently progressing toward its first clinical candidate.